ANG Lifesciences India Ltd () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Veerhealth Care

JFL Life

Vineet Laborator

Sandu Pharma.

Roopa Industries

ANG Lifesciences

Medi Caps

Mangalam Drugs

Dipna Pharmachem

Guj. Inject(Ker)

Mono Pharmacare

Why is ANG Lifesciences India Ltd ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Net Sales has grown by an annual rate of -30.82% and Operating profit at -164.88% over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of 52.88 times

The company has declared Negative results for the last 14 consecutive quarters

NET SALES(Q) At Rs 26.05 cr has Fallen at -20.77%
PBT LESS OI(Q) At Rs -3.33 cr has Fallen at -103.05%
DEBT-EQUITY RATIO(HY) Highest at 1.52 times

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -38.31%, its profits have risen by 6.1%

44.88% of Promoter Shares are Pledged

In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -38.31% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ANG Lifesciences for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

ANG Lifesciences

-39.53%

-0.80

47.66%

Sensex

4.55%

0.45

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-30.82%

EBIT Growth (5y)

-164.88%

EBIT to Interest (avg)

0.01

Debt to EBITDA (avg)

6.48

Net Debt to Equity (avg)

1.46

Sales to Capital Employed (avg)

1.16

Tax Ratio

24.80%

Dividend Payout Ratio

Pledged Shares

44.88%

Institutional Holding

ROCE (avg)

5.28%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.64

EV to EBIT

-14.46

EV to EBITDA

-57.91

EV to Capital Employed

0.85

EV to Sales

1.34

PEG Ratio

Dividend Yield

ROCE (Latest)

-5.90%

ROE (Latest)

-20.69%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-15What is not working for the Company

NET SALES(Q)

At Rs 26.05 cr has Fallen at -20.77%

PBT LESS OI(Q)

At Rs -3.33 cr has Fallen at -103.05%

DEBT-EQUITY RATIO(HY)

Highest at 1.52 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.06 times

DPS(Y)

Lowest at Rs 0.00

DPR(Y)

Lowest at 0.00%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 3.58 cr

Loading Valuation Snapshot...

Here's what is not working for ANG Lifesciences

Net Sales - Quarterly

At Rs 26.05 cr has Fallen at -20.77%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs -3.33 cr has Fallen at -103.05%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Debt-Equity Ratio - Half Yearly

Highest at 1.52 times and Grown

each half year in the last five half yearly periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio- Half Yearly

Lowest at 1.06 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 3.58 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Dividend per Share (DPS) - Annually

Lowest at Rs 0.00

in the last five years

MOJO Watch

Company is distributing lower dividend than previous years

DPS (Rs)

Dividend Payout Ratio (DPR) - Annually

Lowest at 0.00%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)